8-K: ImmuCell Announces Strong 2024 Results with 52% Sales Increase and Positive EBITDA

ImmuCell Corporation reports a 52% increase in product sales for both the fourth quarter and full year of 2024, along with a shift to positive EBITDA.

Summary

• ImmuCell Corporation announced its unaudited financial results for the quarter and year ended December 31, 2024.
• Product sales for the fourth quarter of 2024 increased by 52% to approximately $7.8 million compared to the same period in 2023.
• Full-year product sales for 2024 also increased by 52% to approximately $26.5 million compared to 2023.
• The company reported a gross margin of 37% for the fourth quarter of 2024, up from 25% in the fourth quarter of 2023.
• For the full year, the gross margin improved to 30% in 2024 from 22% in 2023.
• Net income for the fourth quarter of 2024 was $515,000, or $0.06 per diluted share, compared to a net loss of $1,140,000, or $0.15 per basic share, in the same period of 2023.
• The net loss for the full year 2024 was $2,157,000, or $0.26 per basic share, compared to a net loss of $5,775,000, or $0.75 per basic share, in 2023.
• EBITDA improved to approximately $1,331,000 for the fourth quarter of 2024, compared to a negative EBITDA of approximately $311,000 in the fourth quarter of 2023.
• For the full year, EBITDA improved to approximately $1,109,000 in 2024, compared to a negative EBITDA of approximately $2,577,000 in 2023.
• Cash and cash equivalents increased to $3.8 million as of December 31, 2024, from $979,000 as of December 31, 2023.
• Net working capital increased to approximately $10.6 million as of December 31, 2024, from $7.3 million as of December 31, 2023.
• Stockholders' equity increased to $27.5 million as of December 31, 2024, from $25 million as of December 31, 2023.
• The company is awaiting FDA approval to commercialize Re-Tain, with a controlled launch pending FDA clearance of inspectional observations and review of the Non-Administrative NADA submission.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant improvements in sales, gross margin, and EBITDA. The company's recovery from previous production issues and its focus on future growth contribute to the positive sentiment.

Positives

• Significant increase in product sales for both the quarter and the year.
• Improved gross margins compared to the previous year.
• Shift from negative to positive EBITDA for both the quarter and the year.
• Increased cash and cash equivalents.
• Increased net working capital.
• Increased stockholders' equity.
• The company has operated without another contamination event since April 2024.

Negatives

• The company still reported a net loss for the full year 2024, although it was significantly reduced compared to 2023.
• The launch of Re-Tain is pending FDA approval, which introduces uncertainty.

Risks

• The company's future performance depends on obtaining regulatory approvals, particularly for Re-Tain.
• Delays in regulatory approvals could impact the company's ability to commercialize new products.
• The company faces competition within its product markets.
• Supply chain disruptions could adversely impact operations.
• Commercial and operational risks are associated with the expansion of production capacity.

Future Outlook

The company is focused on improving production yields and gross margins and is working to achieve FDA approval to commercialize Re-Tain, with a controlled launch pending FDA clearance of inspectional observations and review of the Non-Administrative NADA submission.

Management Comments

• We have no changes to those figures.
• We have continued to operate without another contamination event since April of 2024, which leads us to believe that we have effectively remediated the problem and are keeping the bioburden within specification.
• We are now focused on improving our production yields and gross margins.
• The significant increase in sales over prior periods demonstrates the beginning of our recovery from a period when production was limited due to contamination events.
• This sales growth, together with an improvement in gross margin from 25% during the fourth quarter of 2023 to 37% during the fourth quarter of 2024, helped us move EBITDA from negative to positive during the quarter and the year ended December 31, 2024, in contrast to negative EBITDA during the same periods of the prior year.
• We continue to work to achieve FDA approval to commercialize Re-Tain.

Industry Context

ImmuCell operates in the animal health industry, specifically focusing on products for dairy and beef cattle. The company's growth and improved financial performance reflect a recovery from previous production limitations and a growing demand for its products. The successful launch of Re-Tain would further strengthen its position in the market.

Comparison to Industry Standards

• It is difficult to compare ImmuCell directly to industry giants like Zoetis or Elanco, as they have a much broader product portfolio and global reach.
• However, within the niche of mastitis treatment and prevention, companies like Boehringer Ingelheim (with products like Orbeseal) and Merck Animal Health (with products like Spectramast) are relevant competitors.
• ImmuCell's focus on products without milk discard requirements (like Re-Tain aims to be) differentiates it from many traditional antibiotic treatments, aligning with the growing trend towards responsible antibiotic use in animal agriculture.
• A 52% sales increase is a strong performance compared to the average growth rates in the animal health industry, which typically range from 3-7% annually.

Stakeholder Impact

• Shareholders will likely react positively to the improved financial performance and future growth prospects.
• Employees may benefit from the company's success through potential bonuses or increased job security.
• Customers (dairy and beef farmers) will have access to improved products and solutions for animal health.
• Suppliers may see increased demand for their products and services as ImmuCell's production expands.

Next Steps

• The company plans to host a conference call on February 26, 2025, to discuss the financial results.
• The company is awaiting FDA approval for Re-Tain and plans a controlled launch upon approval.
• The company will continue to focus on improving production yields and gross margins.

Key Dates